PHARMACEUTICAL PREPARATION

摘要

PURPOSE: A pharmaceutical formulation comprising an immediate release fraction and a sustained release fraction is provided to induce optimal pharmacological effects. CONSTITUTION: A pharmaceutical formulation comprises an immediate release fraction containing rennin inhibitors as a pharmacologically active ingredient; and a sustained release fraction containing dihydropyridine calcium channel blockers as a pharmacologically active ingredient. The rennin inhibitor is aliskiren hemi-fumarate. The calcium channel blocker is amlophidine besylate salt. The pharmaceutical formulation is used for preventing or treating metabolic syndrome, cardiovascular diseases, and renal disorders.